RANKINGS

Key list: leading companies by R&D expenditure in South Korea

Powered by 

This month our pharma industry key list brings you the 15 leading companies in South Korea by R&D expenditure, as ranked by GlobalData's Pharma Intelligence Centre. All numbers up to date as of December 2020.

Company name

Entity type

Number of employeesR&D expenditure ($m)

Hanmi Pharmaceuticals Co Ltd

Public2,419151

Daewoong Co Ltd

Public714119

Green Cross Holdings Corp

Public170111

Daewoong Pharmaceutical Co Ltd

Public1,464104

Celltrion Inc

Public1,07483

Chong Kun Dang Pharmaceutical Corp

Public1,90470

Yuhan Corp

Public1,82067

Genexine Inc

Public-30

Boryung Pharmaceutical Co Ltd

Public1,14429

Huons Global Co Ltd

Public54126

Handok Inc

Public95325

Bukwang Pharmaceutical Co Ltd

Public-21

Kolon Life Science Inc

Public48918

Dong-A Socio Holdings Co Ltd

Public5,48316

Dongkook Pharmaceutical Co Ltd

Public-15
Go to article: Home | Is Joe Biden good news for US pharma?Go to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: CommentGo to article: Pipeline agents in the RA marketGo to article: US seeing alarming increases in Covid-19 casesGo to article: IDMP: Where are we now and what lies ahead?Go to article: The rising role of the microbiomeGo to article: What the pandemic highlights about IDMP’s potentialGo to article: In DepthGo to article: Solving the puzzle of Hepatitis CGo to article: Why is President-elect Joe Biden a good pick for the pharma industry?Go to article: Is self-medication the future of pharma?Go to article: Restricted growth: Challenging attitudes to achondroplasiaGo to article: How do you fast-track a vaccine? UCL scientists weigh in Go to article: Fraudulent pharmaceuticals: the legacy of anti-counterfeit packagingGo to article: Are healthcare’s sustainability goals bold enough?Go to article: New Zealand: a promising destination for trials in a post-Covid-19 world?Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue